Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients

A controlled pilot study

Teresa Santantonio, Grazia Anna Niro, Emanuele Sinisi, Gioacchino Leandro, Maria Insalata, Angela Guastadisegni, Domenico Facciorusso, Eleonora Gravinese, Angelo Andriulli, Giuseppe Pastore

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Background/Aims: In this study, lamivudine-interferon (LAM/IFN) combination therapy was compared to LAM monotherapy to verify if the combination treatment might improve efficacy and reduce the emergence of LAM-resistant mutants. Methods: Fifty patients with anti-HBe-positive chronic hepatitis B were treated for 12 months with LAM at 100 mg/ day (26 pts) or with IFN at 5 MU t.i.w. + LAM 100 mg/day (24 pts). Serum ALT, HBV DNA and IgM anti-HBc were monitored during treatment and a 6-month follow-up. The polymerase gene was amplified by PCR and the region coding for YMDD motif was directly sequenced. Results: All patients normalized ALT and cleared HBV DNA during treatment. The response was maintained until the end of therapy in the LAM/IFN group, while in 5/26 initial responders treated with LAM alone, a virological and biochemical breakthrough was observed after 6-10 months, and selection for YMDD variants resulted. After therapy discontinuation, most patients relapsed; the response rate after 6 months was 17 % in the LAM/IFN group and 19 % in the LAM group. Conclusions: In anti-HBe-positive chronic hepatitis B, a 12-month course of LAM/IFN combination therapy is as beneficial as LAM monotherapy, however, the combination regimen appeared to prevent or delay the emergence of YMDD variants.

Original languageEnglish
Pages (from-to)799-804
Number of pages6
JournalJournal of Hepatology
Volume36
Issue number6
DOIs
Publication statusPublished - Jun 1 2002

Fingerprint

Lamivudine
Chronic Hepatitis B
Interferons
Therapeutics
DNA
lipoarabinomannan
Polymerase Chain Reaction
Serum
Genes

Keywords

  • Anti-HBe positive chronic hepatitis B
  • Antiviral therapy
  • Combination therapy
  • Drug resistance
  • Interferon
  • Lamivudine
  • YMDD mutants

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients : A controlled pilot study. / Santantonio, Teresa; Anna Niro, Grazia; Sinisi, Emanuele; Leandro, Gioacchino; Insalata, Maria; Guastadisegni, Angela; Facciorusso, Domenico; Gravinese, Eleonora; Andriulli, Angelo; Pastore, Giuseppe.

In: Journal of Hepatology, Vol. 36, No. 6, 01.06.2002, p. 799-804.

Research output: Contribution to journalArticle

Santantonio, Teresa ; Anna Niro, Grazia ; Sinisi, Emanuele ; Leandro, Gioacchino ; Insalata, Maria ; Guastadisegni, Angela ; Facciorusso, Domenico ; Gravinese, Eleonora ; Andriulli, Angelo ; Pastore, Giuseppe. / Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients : A controlled pilot study. In: Journal of Hepatology. 2002 ; Vol. 36, No. 6. pp. 799-804.
@article{ab08a99766204e3d932b8cd406ae1984,
title = "Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: A controlled pilot study",
abstract = "Background/Aims: In this study, lamivudine-interferon (LAM/IFN) combination therapy was compared to LAM monotherapy to verify if the combination treatment might improve efficacy and reduce the emergence of LAM-resistant mutants. Methods: Fifty patients with anti-HBe-positive chronic hepatitis B were treated for 12 months with LAM at 100 mg/ day (26 pts) or with IFN at 5 MU t.i.w. + LAM 100 mg/day (24 pts). Serum ALT, HBV DNA and IgM anti-HBc were monitored during treatment and a 6-month follow-up. The polymerase gene was amplified by PCR and the region coding for YMDD motif was directly sequenced. Results: All patients normalized ALT and cleared HBV DNA during treatment. The response was maintained until the end of therapy in the LAM/IFN group, while in 5/26 initial responders treated with LAM alone, a virological and biochemical breakthrough was observed after 6-10 months, and selection for YMDD variants resulted. After therapy discontinuation, most patients relapsed; the response rate after 6 months was 17 {\%} in the LAM/IFN group and 19 {\%} in the LAM group. Conclusions: In anti-HBe-positive chronic hepatitis B, a 12-month course of LAM/IFN combination therapy is as beneficial as LAM monotherapy, however, the combination regimen appeared to prevent or delay the emergence of YMDD variants.",
keywords = "Anti-HBe positive chronic hepatitis B, Antiviral therapy, Combination therapy, Drug resistance, Interferon, Lamivudine, YMDD mutants",
author = "Teresa Santantonio and {Anna Niro}, Grazia and Emanuele Sinisi and Gioacchino Leandro and Maria Insalata and Angela Guastadisegni and Domenico Facciorusso and Eleonora Gravinese and Angelo Andriulli and Giuseppe Pastore",
year = "2002",
month = "6",
day = "1",
doi = "10.1016/S0168-8278(02)00056-9",
language = "English",
volume = "36",
pages = "799--804",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "6",

}

TY - JOUR

T1 - Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients

T2 - A controlled pilot study

AU - Santantonio, Teresa

AU - Anna Niro, Grazia

AU - Sinisi, Emanuele

AU - Leandro, Gioacchino

AU - Insalata, Maria

AU - Guastadisegni, Angela

AU - Facciorusso, Domenico

AU - Gravinese, Eleonora

AU - Andriulli, Angelo

AU - Pastore, Giuseppe

PY - 2002/6/1

Y1 - 2002/6/1

N2 - Background/Aims: In this study, lamivudine-interferon (LAM/IFN) combination therapy was compared to LAM monotherapy to verify if the combination treatment might improve efficacy and reduce the emergence of LAM-resistant mutants. Methods: Fifty patients with anti-HBe-positive chronic hepatitis B were treated for 12 months with LAM at 100 mg/ day (26 pts) or with IFN at 5 MU t.i.w. + LAM 100 mg/day (24 pts). Serum ALT, HBV DNA and IgM anti-HBc were monitored during treatment and a 6-month follow-up. The polymerase gene was amplified by PCR and the region coding for YMDD motif was directly sequenced. Results: All patients normalized ALT and cleared HBV DNA during treatment. The response was maintained until the end of therapy in the LAM/IFN group, while in 5/26 initial responders treated with LAM alone, a virological and biochemical breakthrough was observed after 6-10 months, and selection for YMDD variants resulted. After therapy discontinuation, most patients relapsed; the response rate after 6 months was 17 % in the LAM/IFN group and 19 % in the LAM group. Conclusions: In anti-HBe-positive chronic hepatitis B, a 12-month course of LAM/IFN combination therapy is as beneficial as LAM monotherapy, however, the combination regimen appeared to prevent or delay the emergence of YMDD variants.

AB - Background/Aims: In this study, lamivudine-interferon (LAM/IFN) combination therapy was compared to LAM monotherapy to verify if the combination treatment might improve efficacy and reduce the emergence of LAM-resistant mutants. Methods: Fifty patients with anti-HBe-positive chronic hepatitis B were treated for 12 months with LAM at 100 mg/ day (26 pts) or with IFN at 5 MU t.i.w. + LAM 100 mg/day (24 pts). Serum ALT, HBV DNA and IgM anti-HBc were monitored during treatment and a 6-month follow-up. The polymerase gene was amplified by PCR and the region coding for YMDD motif was directly sequenced. Results: All patients normalized ALT and cleared HBV DNA during treatment. The response was maintained until the end of therapy in the LAM/IFN group, while in 5/26 initial responders treated with LAM alone, a virological and biochemical breakthrough was observed after 6-10 months, and selection for YMDD variants resulted. After therapy discontinuation, most patients relapsed; the response rate after 6 months was 17 % in the LAM/IFN group and 19 % in the LAM group. Conclusions: In anti-HBe-positive chronic hepatitis B, a 12-month course of LAM/IFN combination therapy is as beneficial as LAM monotherapy, however, the combination regimen appeared to prevent or delay the emergence of YMDD variants.

KW - Anti-HBe positive chronic hepatitis B

KW - Antiviral therapy

KW - Combination therapy

KW - Drug resistance

KW - Interferon

KW - Lamivudine

KW - YMDD mutants

UR - http://www.scopus.com/inward/record.url?scp=0036623206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036623206&partnerID=8YFLogxK

U2 - 10.1016/S0168-8278(02)00056-9

DO - 10.1016/S0168-8278(02)00056-9

M3 - Article

VL - 36

SP - 799

EP - 804

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 6

ER -